enGene Therapeutics (ENGN) Common Equity (2022 - 2026)
enGene Therapeutics (ENGN) posted quarterly Common Equity of $255.2 million for Q2 2026, up 12.26% year-over-year from $227.3 million in Q2 2025, and down 9.37% quarter-over-quarter from $281.5 million in Q1 2026.
enGene Therapeutics (ENGN) Common Equity (2022 - 2026) Analysis & Trends
enGene Therapeutics (ENGN) has reported Common Equity for 5 consecutive years, with $255.2 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Common Equity rose 12.26% year-over-year to $255.2 million; the TTM figure through Apr 2026 stood at $255.2 million (up 12.26% YoY), while the FY2025 annual figure was $167.7 million, down 38.48% from the prior year.
- Common Equity slipped to $255.2 million in Q2 2026 per ENGN's latest filing, from $281.5 million in the prior quarter.
- Across five years, Common Equity topped out at $281.5 million in Q1 2026 and bottomed at -$93.9 million in Q3 2023.
- Historically, Common Equity has averaged $128.0 million across 5 years, with a median of $200.7 million in 2025.
- Annual changes were most pronounced in 2024 — Common Equity jumped 372.27% — and 2025, when it plunged 38.48%.
- enGene Therapeutics' Common Equity stood at -$76.6 million in 2022, then surged by 194.61% to $72.5 million in 2023, then soared by 276.09% to $272.6 million in 2024, then slumped by 38.48% to $167.7 million in 2025, then jumped by 52.15% to $255.2 million in 2026.
- Business Quant data shows ENGN's Common Equity at $255.2 million in Q2 2026, $281.5 million in Q1 2026, and $167.7 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.90 Bn | 132.05 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 65.73 Bn | 60.55 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.33 Bn | 53.19 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.72 Bn | 28.42 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.27 Bn | 9.88 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.25 Bn | 26.41 Bn | - | 9.79 Bn |
| 10 | enGene Therapeutics | 124.81 Mn | 124.81 Mn | - | 255.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 255.17 Mn |
| Jan 31, 2026 | 281.55 Mn |
| Oct 31, 2025 | 167.71 Mn |
| Jul 31, 2025 | 200.67 Mn |
| Apr 30, 2025 | 227.29 Mn |
| Jan 31, 2025 | 249.95 Mn |
| Oct 31, 2024 | 272.61 Mn |
| Jul 31, 2024 | 230.33 Mn |
| Apr 30, 2024 | 242.97 Mn |
| Jan 31, 2024 | 62.39 Mn |
| Oct 31, 2023 | 72.49 Mn |
| Jul 31, 2023 | -93.92 Mn |
| Apr 30, 2023 | -89.24 Mn |
| Jan 31, 2023 | -84.01 Mn |
| Oct 31, 2022 | -76.61 Mn |